Cullen/Frost Bankers, Inc. Vaxcyte, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.83 Billion
- Q2 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 380 shares of PCVX stock, worth $16,210. This represents 0.0% of its overall portfolio holdings.
Number of Shares
380
Previous 204
86.27%
Holding current value
$16,210
Previous $7,000
71.43%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$627 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$512 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$510 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$424 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$256 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.53B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...